Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures

Published 14/07/2022, 14:01
Updated 14/07/2022, 14:40
© Reuters.  The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures

© Reuters. The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures

Here's a roundup of top developments in the biotech space over the last 24 hours:

Stocks In Focus Novavax Receives Much Awaited FDA Nod For Protein-Based COVID-19 Vaccine The FDA granted emergency use authorization to Novavax Inc (NASDAQ: NVAX)'s adjuvanted COVID-19 vaccine (NVX-CoV2373) as a two-dose primary series for active immunization for individuals 18 years of age and over.

"Today's FDA emergency use authorization of our COVID-19 vaccine provides the U.S. with access to the first protein-based COVID-19 vaccine," said Stanley Erck, Novavax's president and CEO.

Shares are up 1.47% at $70.98 during the premarket session.

CytomX Therapeutics Cuts Workforce, Extend Cash Runway Into 2025 CytomX Therapeutics Inc (NASDAQ: CTMX) is restructuring its business to prioritize internal investments in its emerging pre-clinical and early clinical pipeline.

The company will cut 40% of its workforce. The changes are expected to extend the company's cash runway into 2025.

The company said that based on the results of a three-arm Phase 2 study of Praluzatamab ravtansine in breast cancer, it would deprioritize internal investment in this program and seek a partnership to advance the asset further.

Shares are up 4.62% at $1.36 during the premarket session.

Independent Monitoring Board Recommends Halt Of ContraFect's Exebacase Phase 3 Study Following interim futility analysis, the Data Safety Monitoring Board recommended that ContraFect Corporation's (NASDAQ: CFRX) Phase 3 DISRUPT study of exebacase be stopped because the conditional power of the study was below the pre-specified threshold for futility.

The recommendation was based on an analysis of the clinical response rate at day 14 in 84 patients, or approximately 60% of the total planned methicillin-resistant Staphylococcus aureus population.

Further review of the data is ongoing.

Shares are slipping 77.2% at 65 cents during the premarket session.

Royalty Pharma To Acquire Trelegy Royalty From Theravance, Innoviva Royalty Pharma plc (NASDAQ: RPRX) agreed to acquire a royalty interest in Trelegy from Theravance Biopharma Inc (NASDAQ: TBPH) and Innoviva Inc (NASDAQ: INVA) for $1.31 billion upfront and up to $300 million in milestone payments.

Trelegy, marketed by GSK Plc (NYSE: GSK), combines an inhaled corticosteroid and two bronchodilators in a single delivery device to maintain chronic obstructive pulmonary disease (COPD) and the maintenance treatment of asthma.

Click here to access Benzinga's FDA Calendar.

Regeneron-Sanofi's Dupixent Hits Primary Goal In Esophagitis Patients Below 11 Years Regeneron Pharmaceuticals Inc (NASDAQ: NASDAQ:REGN) and Sanofi (EPA:SASY) SA's (NASDAQ: SNY) Phase 3 trial of Dupixent (dupilumab) in children ages 1 to 11 years with eosinophilic esophagitis (EoE) met its primary endpoint of histological disease remission at 16 weeks.

68% of children on a higher dose and 58% of patients on a lower dose of Dupixent achieved histological disease remission compared to 3% of children on placebo.

FDA Pushes Out Action On BeiGene's Tislelizumab For Esophagus Cancer The FDA has deferred action on the Biologics License Application for BeiGene Ltd's (NASDAQ: BGNE) tislelizumab as a second-line treatment of unresectable or metastatic esophageal squamous cell carcinoma.

The FDA has been unable to conduct required inspections in China due to COVID-19-related travel restrictions. As a result, the FDA is deferring action on the application until the inspections are complete.

Shares are slipping 6.71% at $158.35 during the premarket session.

Lantern Pharma Receives FDA Nod For Midstage Study Of LP-300 in Nonsmokers With Lung Cancer The FDA has signed off Lantern Pharma Inc's (NASDAQ: LTRN) Phase 2 Harmonic trial for LP-300.

The 90-patient trial will evaluate LP-300 in combination with chemotherapy for never-smoker patients with advanced non-small cell lung cancer.

Shares are up 11.8% at $6.53 during the premarket session.

Marinus Sells Rare Pediatric Disease Priority Voucher For $110M Marinus Pharmaceuticals Inc (NASDAQ: MRNS) has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $110 million to Novo Nordisk (CSE:NOVOb) A/S (NYSE: NVO).

"Upon completion, the sale of the PRV will significantly strengthen Marinus' financial position, which we believe extends our cash runway into the fourth quarter of 2023," said Steven Pfanstiel, CFO of Marinus.

Marinus received the voucher in March 2022 after it received approval of Ztalmy (ganaxolone) oral suspension CV for seizures associated with CDKL5 deficiency disorder, a rare form of genetic epilepsy, in patients two years of age and older.

Shares are up 5.41% at $5.85 during the premarket session.

Amryt Receives FDA Orphan Drug Tag For Mycapssa In Carcinoid Syndrome The FDA has granted orphan drug designation to Amryt Pharma PLC (NASDAQ: AMYT)'s Mycapssa for carcinoid syndrome, the most common functional syndrome associated with neuroendocrine tumors.

Offerings BELLUS Health Inc (NASDAQ: BLU) priced its public offering of 16.5 million shares at $9.25, with gross proceeds equivalent to $153 million.

Shares are down 8.82% at $9.20 during the premarket session.

On The Radar Earnings Theratechnologies Inc (NASDAQ: THTX): Before the market open.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.